tradingkey.logo

Evoke Pharma Inc

EVOK
11.000USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
18.95MMarket Cap
LossP/E TTM

Evoke Pharma Inc

11.000
0.0000.00%

More Details of Evoke Pharma Inc Company

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

Evoke Pharma Inc Info

Ticker SymbolEVOK
Company nameEvoke Pharma Inc
IPO dateSep 25, 2013
CEOD'Onofrio (Matthew J)
Number of employees3
Security typeOrdinary Share
Fiscal year-endSep 25
Address420 Stevens Avenue
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone18583451494
Websitehttps://evokepharma.com/
Ticker SymbolEVOK
IPO dateSep 25, 2013
CEOD'Onofrio (Matthew J)

Company Executives of Evoke Pharma Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+1318.00%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-1.00%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
--
-27.00%
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
--
-133.00%
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Mr. Mark A. Kowieski
Mr. Mark A. Kowieski
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+1318.00%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-1.00%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
--
-27.00%
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--

Revenue Breakdown

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
DRW Securities, LLC
1.38%
Two Sigma Investments, LP
0.61%
D'Onofrio (Matthew J)
0.57%
Other
79.48%
Shareholders
Shareholders
Proportion
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
DRW Securities, LLC
1.38%
Two Sigma Investments, LP
0.61%
D'Onofrio (Matthew J)
0.57%
Other
79.48%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.59%
Investment Advisor
10.08%
Hedge Fund
0.61%
Research Firm
0.01%
Other
78.71%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
502.38K
22.98%
--
2025Q3
26
502.38K
25.40%
+260.79K
2025Q2
25
242.44K
26.58%
-10.18K
2025Q1
28
252.99K
24.26%
-109.24K
2024Q4
30
218.46K
24.86%
-81.81K
2024Q3
31
208.32K
29.69%
-54.34K
2024Q2
31
262.66K
432.25%
-959.00
2024Q1
39
263.62K
30.12%
+47.85K
2023Q4
36
5.70K
3.76%
+99.00
2023Q3
40
5.65K
7.83%
+642.00
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Klein (Roger M.)
163.00K
9.46%
+163.00K
--
Nov 04, 2025
Bleichroeder LP
146.40K
8.5%
+77.64K
+112.94%
Sep 30, 2025
DRW Securities, LLC
23.74K
1.38%
+23.74K
--
Sep 30, 2025
Two Sigma Investments, LP
10.44K
0.61%
+10.44K
--
Sep 30, 2025
D'Onofrio (Matthew J)
9.82K
0.57%
+1.32K
+15.50%
Mar 24, 2025
Kowieski (Mark A.)
4.92K
0.29%
+4.92K
--
Mar 24, 2025
Osaic Holdings, Inc.
3.01K
0.17%
+3.01K
--
Sep 30, 2025
Gonyer (David A)
2.36K
0.14%
-1.00
-0.04%
Mar 24, 2025
Garner (Cam L)
2.33K
0.14%
-1.00
-0.04%
Mar 24, 2025
Northwestern Mutual Capital, LLC
272.00
0.02%
+272.00
--
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
Date
Ex-dividend Date
Type
Ratio
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
KeyAI